Hilal Çakır Taşkın
Hilal Çakır Taşkın has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Adem Kose
Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Inonu University, Malatya, Turkey
1 shared publication - Ahmet Tahiroğlu1 shared publication
- Ahmet Özcan
Department of Internal Medicine, Division of Endocrinology, Faculty of Medicine Suleyman Demirel University Isparta Türkiye
1 shared publication - Aleyna Doyran1 shared publication
- Ayhan Levent1 shared publication
- Aykut Yaman1 shared publication
Latest Publications
- 19 November 2026
- Published by Academician Publishing
- p. 259-266
Sekonder Hipertansiyonun Nadir Ancak Tedavi Edilebilir Nedeni: Conn Sendromu
- 19 November 2026
- Published by Academician Publishing
- p. 259-266
Sekonder Hipertansiyonun Nadir Ancak Tedavi Edilebilir Nedeni: Conn Sendromu
- 19 November 2026
- Published by Academician Publishing
Olgular Eşliğinde Genel Dahiliye III
- 23 September 2026
- Published by Istanbul University in International Journal of Environment and Geoinformatics
- Vol. 13 (3) , 247-254
Endocrine-Disrupting Chemicals from Synthetic Food-Contact Polymers as an Internal Medicine Concern: A Preliminary Assessment of Marine-Derived Sodium Alginate as a Potential Packaging Biomaterial
Petroleum-based polymers such as polyvinyl chloride, polyethylene terephthalate, polycarbonate and epoxy resins dominate the food-packaging sector, yet chemicals migrating from these materials represent a potentially important source of chronic human exposure with relevance to internal medicine. Bisphenol A (BPA), phthalates, oligomers, non-intentionally added substances and micro/nanoplastics have been detected in food-contact materials and human samples and have been associated with endocrine, metabolic, hepatic and cardiovascular outcomes. Reducing exposure at the packaging source is therefore an important preventive-medicine consideration. This study presents a preliminary materials assessment of sodium alginate extracted from the invasive brown macroalga Cystoseira barbata collected from the Şile coast of the Black Sea, with particular consideration of its potential as a marine-derived biomaterial for food-packaging applications. Alginate was recovered by formaldehyde pre-treatment, acid conditioning, sodium-carbonate extraction and double ethanol precipitation and was characterized by Fourier-transform infrared (FT-IR) spectroscopy. The FT-IR spectrum confirmed the characteristic hydroxyl, carboxylate and glycosidic bands of the alginate polysaccharide structure, with no evident structural degradation. The low mannuronic-to-guluronic (M/G) ratio reported for this species (~0.65) suggests potentially favourable material characteristics for film formation based on previously reported structure–property relationships. Sodium alginate is an established food-grade hydrocolloid (E 401) with a long history of food and pharmaceutical use. These characteristics support further investigation of C. barbata-derived alginate as a potential biomaterial for food-contact applications. However, the present study does not establish packaging safety, migration performance, mechanical or barrier properties, or a clinically meaningful reduction in exposure to endocrine-disrupting chemicals. Such claims require dedicated migration, mechanical, barrier, microbiological and toxicological studies.
- 23 September 2026
- Published by Istanbul University in International Journal of Environment and Geoinformatics
- Vol. 13 (3) , 247-254
Endocrine-Disrupting Chemicals from Synthetic Food-Contact Polymers as an Internal Medicine Concern: A Preliminary Assessment of Marine-Derived Sodium Alginate as a Potential Packaging Biomaterial
Petroleum-based polymers such as polyvinyl chloride, polyethylene terephthalate, polycarbonate and epoxy resins dominate the food-packaging sector, yet chemicals migrating from these materials represent a potentially important source of chronic human exposure with relevance to internal medicine. Bisphenol A (BPA), phthalates, oligomers, non-intentionally added substances and micro/nanoplastics have been detected in food-contact materials and human samples and have been associated with endocrine, metabolic, hepatic and cardiovascular outcomes. Reducing exposure at the packaging source is therefore an important preventive-medicine consideration. This study presents a preliminary materials assessment of sodium alginate extracted from the invasive brown macroalga Cystoseira barbata collected from the Şile coast of the Black Sea, with particular consideration of its potential as a marine-derived biomaterial for food-packaging applications. Alginate was recovered by formaldehyde pre-treatment, acid conditioning, sodium-carbonate extraction and double ethanol precipitation and was characterized by Fourier-transform infrared (FT-IR) spectroscopy. The FT-IR spectrum confirmed the characteristic hydroxyl, carboxylate and glycosidic bands of the alginate polysaccharide structure, with no evident structural degradation. The low mannuronic-to-guluronic (M/G) ratio reported for this species (~0.65) suggests potentially favourable material characteristics for film formation based on previously reported structure–property relationships. Sodium alginate is an established food-grade hydrocolloid (E 401) with a long history of food and pharmaceutical use. These characteristics support further investigation of C. barbata-derived alginate as a potential biomaterial for food-contact applications. However, the present study does not establish packaging safety, migration performance, mechanical or barrier properties, or a clinically meaningful reduction in exposure to endocrine-disrupting chemicals. Such claims require dedicated migration, mechanical, barrier, microbiological and toxicological studies.
- Open Access
- 8 August 2026
- Published by Elsevier in SSRN Electronic Journal
Artificial Intelligence-Assisted Health Information Seeking and Its Association with Trust in Physicians: A Cross-Sectional Study Among Internal Medicine Outpatients in Turkiye
Patients increasingly use generative artificial intelligence (AI) tools to obtain health information, yet evidence on how this relates to trust in physicians is limited, particularly outside high-income settings. This cross-sectional study surveyed 526 adult patients attending the Internal Medicine outpatient clinic of a tertiary hospital in Istanbul, Turkey, using a 33-item self-administered questionnaire covering internet-based health information seeking (11 items, informed by the eHealth Literacy Scale framework), AI use and attitudes (6 items), trust in physicians (5 items), and AI–physician comparative preferences (5 items). Reliability (Cronbach’s α, principal component analysis), two-group comparisons (Mann–Whitney U, chi-square), Spearman correlations, and multivariable binary logistic regression were performed. Overall, 70.7% of patients had asked an AI tool a health-related question, yet attitudes remained cautious: 20.9% trusted AI in healthcare and 6.5% would change treatment based on AI advice. Trust in physicians was high (composite 4.14 ± 0.80 of 5; α = 0.92) and did not differ between AI users and non-users (p = 0.290). In multivariable regression, younger age (aOR 0.93 per year, 95% CI 0.91–0.95) and higher education (postgraduate aOR 6.27, 95% CI 2.20–17.88) independently predicted AI use. AI attitudes correlated weakly and negatively with physician trust (ρ = −0.107, p = 0.014); 43.3% endorsed combined AI–physician use and 4.4% would accept AI-only treatment. AI-assisted health information seeking is already common among Turkish internal medicine outpatients, especially younger and more educated patients, while trust in physicians remains largely intact. The findings support a complementary, physician-led model of AI integration into outpatient care.
- 8 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessArtificial Intelligence-Assisted Health Information Seeking and Its Association with Trust in Physicians: A Cross-Sectional Study Among Internal Medicine Outpatients in Turkiye
Patients increasingly use generative artificial intelligence (AI) tools to obtain health information, yet evidence on how this relates to trust in physicians is limited, particularly outside high-income settings. This cross-sectional study surveyed 526 adult patients attending the Internal Medicine outpatient clinic of a tertiary hospital in Istanbul, Turkey, using a 33-item self-administered questionnaire covering internet-based health information seeking (11 items, informed by the eHealth Literacy Scale framework), AI use and attitudes (6 items), trust in physicians (5 items), and AI–physician comparative preferences (5 items). Reliability (Cronbach’s α, principal component analysis), two-group comparisons (Mann–Whitney U, chi-square), Spearman correlations, and multivariable binary logistic regression were performed. Overall, 70.7% of patients had asked an AI tool a health-related question, yet attitudes remained cautious: 20.9% trusted AI in healthcare and 6.5% would change treatment based on AI advice. Trust in physicians was high (composite 4.14 ± 0.80 of 5; α = 0.92) and did not differ between AI users and non-users (p = 0.290). In multivariable regression, younger age (aOR 0.93 per year, 95% CI 0.91–0.95) and higher education (postgraduate aOR 6.27, 95% CI 2.20–17.88) independently predicted AI use. AI attitudes correlated weakly and negatively with physician trust (ρ = −0.107, p = 0.014); 43.3% endorsed combined AI–physician use and 4.4% would accept AI-only treatment. AI-assisted health information seeking is already common among Turkish internal medicine outpatients, especially younger and more educated patients, while trust in physicians remains largely intact. The findings support a complementary, physician-led model of AI integration into outpatient care.
- Open Access
- 27 April 2023
- Published by Bandirma Onyedi Eylul Universitesi in Hippocrates Medical Journal
- Vol. 3 (1) , 9-15
Evaluation of Insulin Resistance of Individuals with MAFLD
Introduction: MAFLD is a new diagnosis that has been brought to the terminology in the last 2 years, and it is thought that the main mechanism underlying its development is Insulin Resistance (IR). In our study, it is planned to research the role of IR level in the etiology of patients with MAFLD. Method: 265 individuals with MAFLD are included in the study by examining their sub-parameters of case diagnosis. While 85 patients have T2DM, 180 patients are found to be Prediabetic. IR is calculated with HOMA-IR. The value of 2.5 and above is considered as high, and below 2.5 is considered as normal. The ratios of HOMA-IR levels and their relationship between waist circumference and BMI were examined. Findings: The value of HOMA-IR was found high in 60.6% of prediabetic MAFLDs, while it was normal in 39.4% of them. Age ((p=0.001; p<0.01) and waist circumference (p=0.028; p<0.05) in the T2DM group were found to be higher than the prediabetic group. Very weak positive correlation was found between HOMA-IR and BMI (r=0.223; p=0.003; p<0.01) and waist circumference (r=0.205; p=0.006; p<0.01) in the prediabetic group. In the T2DM group, there was a very weak positive correlation between BMI and HOMA-IR (r=0.254; p=0.019; p<0.05). Conclusion: In our study, IR was not detected in 39.4% of patients with MAFLD. This result leads us to think that insulin sensitizing agents may not be effective in this patient group in patients with normal IR levels. We think that these agents will not be effective in patients with normal IR levels. Our study should be supported with experimental and histological MAFLD studies.
- 27 April 2023
- Published by Bandirma Onyedi Eylul Universitesi in Hippocrates Medical Journal
- Vol. 3 (1) , 9-15
Open AccessEvaluation of Insulin Resistance of Individuals with MAFLD
Introduction: MAFLD is a new diagnosis that has been brought to the terminology in the last 2 years, and it is thought that the main mechanism underlying its development is Insulin Resistance (IR). In our study, it is planned to research the role of IR level in the etiology of patients with MAFLD. Method: 265 individuals with MAFLD are included in the study by examining their sub-parameters of case diagnosis. While 85 patients have T2DM, 180 patients are found to be Prediabetic. IR is calculated with HOMA-IR. The value of 2.5 and above is considered as high, and below 2.5 is considered as normal. The ratios of HOMA-IR levels and their relationship between waist circumference and BMI were examined. Findings: The value of HOMA-IR was found high in 60.6% of prediabetic MAFLDs, while it was normal in 39.4% of them. Age ((p=0.001; p<0.01) and waist circumference (p=0.028; p<0.05) in the T2DM group were found to be higher than the prediabetic group. Very weak positive correlation was found between HOMA-IR and BMI (r=0.223; p=0.003; p<0.01) and waist circumference (r=0.205; p=0.006; p<0.01) in the prediabetic group. In the T2DM group, there was a very weak positive correlation between BMI and HOMA-IR (r=0.254; p=0.019; p<0.05). Conclusion: In our study, IR was not detected in 39.4% of patients with MAFLD. This result leads us to think that insulin sensitizing agents may not be effective in this patient group in patients with normal IR levels. We think that these agents will not be effective in patients with normal IR levels. Our study should be supported with experimental and histological MAFLD studies.
- 12 October 2022
- Published by Academician Publishing
- p. 81-90
Gebelik ve Tiroid Hastalıkları
Gebelik sürecinde tiroid hormonları maternal ve fetal gelişim için kritik bir öneme sahiptir ve tiroid bozuklukları doğurganlık dönemindeki kadınlarda ikinci sıklıkta görülen endokrin patolojidir. Hamilelikle birlikte artan metabolik gereksinimleri karşılamak adına tiroid fonksiyonlarında; östrojen artışına bağlı serum tiroksin bağlayıcı globulin (TBG) yükselmesi, insan koryonik gonadotropini (hCG) etkisiyle geçici TSH düşüklüğü ve idrarla atılım ile fetusa transfer sebebiyle iyot ihtiyacının artması gibi fizyolojik değişiklikler meydana gelir. Fetus ilk 10-12 hafta boyunca tiroid hormonu ihtiyacını tamamen anneden karşıladığından, Türkiye Endokrinoloji ve Metabolizma Derneği (TEMD) gebelik planlayan tüm kadınlara ve gebelere erken dönemde TSH taraması önermektedir. En sık Hashimoto tiroiditine bağlı gelişen hipotiroidi tedavisinde sentetik levotiroksin tercih edilirken ve gebelikte doz artırımı gerekirken; Graves hastalığından kaynaklanan hipertiroidi vakalarında ise ilk trimesterde fetusa zarar vermemek adına propiltiyourasil (PTU) öncelikli olarak tercih edilir. Gebelikte saptanan tiroid nodüllerinde yaklaşım hamile olmayan hastalarla benzerdir ancak tiroid sintigrafisi ve radyoaktif iyot tedavisi gebelikte kesinlikle kontrendikedir. Erken dönemde tanı konulup trimestere özgü referans aralıklarına göre tedavi edilen olgularda erken doğum, preeklampsi, düşük ve bilişsel bozukluk gibi maternal-fetal komplikasyonlar önlenebilmektedir. Thyroid hormones are critically important for maternal and fetal development during pregnancy, and thyroid disorders represent the second most common endocrinopathy in reproductive-aged women. To meet the increased metabolic demands during pregnancy, significant physiological changes occur in thyroid function, including a rise in serum thyroxine-binding globulin (TBG) driven by increased estrogen levels, transiently suppressed TSH due to human chorionic gonadotropin (hCG) stimulation, and an increased requirement for iodine caused by higher renal clearance and transplacental transfer to the fetus. Because the fetus relies entirely on maternal thyroid hormones for the first 10-12 weeks, the Society of Endocrinology and Metabolism of Turkey (TEMD) recommends routine TSH screening for all pregnant women and those planning a pregnancy. Overt hypothyroidism, most commonly caused by Hashimoto's thyroiditis, is treated with synthetic levothyroxine, requiring a dose increase during pregnancy. Conversely, hyperthyroidism, predominantly driven by Graves' disease, is managed with antithyroid medications, where propylthiouracil (PTU) is preferred in the first trimester to mitigate teratogenic risks. Diagnostic approaches for thyroid nodules in pregnancy mirror those for non-pregnant patients; however, thyroid scintigraphy and radioactive iodine therapies are strictly contraindicated. Prompt diagnosis and trimester-specific reference range management effectively prevent complications such as preterm birth, preeclampsia, miscarriage, and fetal cognitive impairment.
- 12 October 2022
- Published by Academician Publishing
- p. 81-90
Gebelik ve Tiroid Hastalıkları
Gebelik sürecinde tiroid hormonları maternal ve fetal gelişim için kritik bir öneme sahiptir ve tiroid bozuklukları doğurganlık dönemindeki kadınlarda ikinci sıklıkta görülen endokrin patolojidir. Hamilelikle birlikte artan metabolik gereksinimleri karşılamak adına tiroid fonksiyonlarında; östrojen artışına bağlı serum tiroksin bağlayıcı globulin (TBG) yükselmesi, insan koryonik gonadotropini (hCG) etkisiyle geçici TSH düşüklüğü ve idrarla atılım ile fetusa transfer sebebiyle iyot ihtiyacının artması gibi fizyolojik değişiklikler meydana gelir. Fetus ilk 10-12 hafta boyunca tiroid hormonu ihtiyacını tamamen anneden karşıladığından, Türkiye Endokrinoloji ve Metabolizma Derneği (TEMD) gebelik planlayan tüm kadınlara ve gebelere erken dönemde TSH taraması önermektedir. En sık Hashimoto tiroiditine bağlı gelişen hipotiroidi tedavisinde sentetik levotiroksin tercih edilirken ve gebelikte doz artırımı gerekirken; Graves hastalığından kaynaklanan hipertiroidi vakalarında ise ilk trimesterde fetusa zarar vermemek adına propiltiyourasil (PTU) öncelikli olarak tercih edilir. Gebelikte saptanan tiroid nodüllerinde yaklaşım hamile olmayan hastalarla benzerdir ancak tiroid sintigrafisi ve radyoaktif iyot tedavisi gebelikte kesinlikle kontrendikedir. Erken dönemde tanı konulup trimestere özgü referans aralıklarına göre tedavi edilen olgularda erken doğum, preeklampsi, düşük ve bilişsel bozukluk gibi maternal-fetal komplikasyonlar önlenebilmektedir. Thyroid hormones are critically important for maternal and fetal development during pregnancy, and thyroid disorders represent the second most common endocrinopathy in reproductive-aged women. To meet the increased metabolic demands during pregnancy, significant physiological changes occur in thyroid function, including a rise in serum thyroxine-binding globulin (TBG) driven by increased estrogen levels, transiently suppressed TSH due to human chorionic gonadotropin (hCG) stimulation, and an increased requirement for iodine caused by higher renal clearance and transplacental transfer to the fetus. Because the fetus relies entirely on maternal thyroid hormones for the first 10-12 weeks, the Society of Endocrinology and Metabolism of Turkey (TEMD) recommends routine TSH screening for all pregnant women and those planning a pregnancy. Overt hypothyroidism, most commonly caused by Hashimoto's thyroiditis, is treated with synthetic levothyroxine, requiring a dose increase during pregnancy. Conversely, hyperthyroidism, predominantly driven by Graves' disease, is managed with antithyroid medications, where propylthiouracil (PTU) is preferred in the first trimester to mitigate teratogenic risks. Diagnostic approaches for thyroid nodules in pregnancy mirror those for non-pregnant patients; however, thyroid scintigraphy and radioactive iodine therapies are strictly contraindicated. Prompt diagnosis and trimester-specific reference range management effectively prevent complications such as preterm birth, preeclampsia, miscarriage, and fetal cognitive impairment.